^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors

Published date:
05/15/2020
Excerpt:
Human endometrial FGFR2-N549K-mutated AN3CA cancer cells were treated with futibatinib plus either everolimus or MK2206 or with each agent alone…In ANC3A cells, the combination of futibatinib with MK2206 inhibited AKT phosphorylation; futibatinib plus either MK2206 or everolimus inhibited mTOR phosphorylation to a greater degree than monotherapy...The combination of futibatinib plus a PI3K pathway inhibitor resulted in synergistic antitumor effects.
DOI:
10.1158/1538-7445.AM2020-659